AG
PCRX icon

Advisor Group’s Pacira BioSciences PCRX Stock Holding History

Advisor Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$65K Sell
1,395
-196
-12% -$8.32K ﹤0.01% 3238
2019
Q3 		$60K Sell
1,591
-314
-16% -$12.5K ﹤0.01% 3251
2019
Q2 		$83K Sell
1,905
-296
-13% -$12.6K ﹤0.01% 2996
2019
Q1 		$83K Sell
2,201
-248
-10% -$9.68K ﹤0.01% 3015
2018
Q4 		$104K Buy
2,449
+223
+10% +$10.4K ﹤0.01% 2623
2018
Q3 		$109K Buy
2,226
+463
+26% +$20K ﹤0.01% 2698
2018
Q2 		$57K Buy
1,763
+21
+1% +$725 ﹤0.01% 2976
2018
Q1 		$55K Buy
1,742
+54
+3% +$1.92K ﹤0.01% 2988
2017
Q4 		$77K Sell
1,688
-186
-10% -$7.37K ﹤0.01% 2768
2017
Q3 		$70K Buy
1,874
+42
+2% +$1.69K ﹤0.01% 2688
2017
Q2 		$88K Buy
1,832
+389
+27% +$18K ﹤0.01% 2414
2017
Q1 		$67K Buy
1,443
+70
+5% +$3.03K ﹤0.01% 2479
2016
Q4 		$44K Sell
1,373
-557
-29% -$18.6K ﹤0.01% 2710
2016
Q3 		$66K Buy
1,930
+233
+14% +$9.13K ﹤0.01% 2302
2016
Q2 		$55K Buy
+1,697
New +$83.4K ﹤0.01% 2357

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Advisor Group's PCRX Position: Q4 2019 in Review

Advisor Group reduced its Pacira BioSciences (PCRX) stake by 12% in Q4 2019, selling an estimated $8.32K and leaving 1,395 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

Advisor Group first reported a position in PCRX in Q2 2016 and has held it in 15 quarters since. The position peaked at $109K in Q3 2018. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

  • Advisor Group held 1,395 shares of Pacira BioSciences worth $65K as of Q4 2019.
  • Advisor Group sold 196 Pacira BioSciences shares in Q4 2019, an estimated $8.32K.
  • Pacira BioSciences made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3238 holding.
  • Advisor Group first reported a position in Pacira BioSciences in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Pacira BioSciences position peaked at $109K in Q3 2018.
  • 231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.